## 4 Discussion
\begin{table}
\begin{tabular}{c c c c c c c c c c c} \hline \hline  & \multicolumn{2}{c}{**Group A**} & \multicolumn{2}{c}{**Group B**} & \multicolumn{2}{c}{**Group A**} & \multicolumn{2}{c}{**Group B**} & \multicolumn{2}{c}{**Inter-**} \\  & **(n = 38)** & & **(n = 39)** & & **Changes** & & **Changes** & & **Action** \\ \cline{2-10}  & **Baseline** & **Post** & **Baseline** & **Post** & \(p\) & **Effect** & **95\% CI** & & **Effect** & **95\% CI** & \\  & & & & & **Size** & **Lower/Upper** & \(p\) & **Size** & **Lower/Upper** & \(p\) \\ \hline VAS & \(6.87\pm 1.838\) & \(3.33\pm 2.017\) & \(6.99\pm 2.331\) & \(3.74\pm 1.117\) & **0.000** * & **0.73** & 2.876/4.211 & **0.047** * & 0.10 & 1.940/3.376 & 0.401 \\ ODI & \(20.58\pm 10.859\) & \(13.00\pm 8.539\) & \(20.82\pm 10.123\) & \(10.38\pm 9.054\) & **0.000** * & **0.63** & 5.671/9.487 & **0.000** * & **0.69** & 8.146/12.725 & 0.169 \\ FTF & \(23.68\pm 18.807\) & \(16.26\pm 17.071\) & \(27.46\pm 17.111\) & \(18.15\pm 19.682\) & **0.000** * & **0.28** & 3.531/11.146 & **0.000** * & **0.51** & 6.335/12.281 & 0.654 \\ TRLF & \(42.58\pm 2.678\) & \(39.04\pm 4.430\) & \(41.04\pm 48.837\) & \(39.70\pm 8.084\) & 0.356 & 0.32 & 3.324/4.834 & 0.509 & 0.12 & 6.029/6.164 & 0.462 \\ TLLE & \(24.18\pm 4.152\) & \(38.42\pm 4.454\) & \(34.22\pm 5.446\) & \(38.26\pm 5.514\) & \(0.097\pm 0.38\) & **0.264** /4.880 & 0.643 & **0.30** & 1.715/3.516 & 0.866 \\ HF & \(64.55\pm 22.002\) & \(82.89\pm 19.920\) & \(55.58\pm 28.013\) & \(70.51\pm 27.381\) & **0.000** * & **0.47** & 1.975/24.709 & **0.000** * & **0.38** & 8.890/13.367 & 0.115 \\ MSTF & \(3.63\pm 0.819\) & \(4.11\pm 0.764\) & \(3.56\pm 0.754\) & \(4.00\pm 6.688\) & **0.018** * & 0.14 & \(-0.657/-0.291\) & 0.844 & 0.07 & 0.664/2.208 & 0.527 \\ MSTF & \(3.37\pm 0.970\) & \(3.84\pm 0.790\) & \(3.44\pm 0.821\) & \(3.90\pm 0.680\) & **0.000** * & 0.58 & 0.672/02.295 & **0.000** & **0.51** & 6.641/0.282 & 0.743 \\ MSTF & \(3.45\pm 0.978\) & \(4.05\pm 0.686\) & \(3.49\pm 0.584\) & \(3.92\pm 0.774\) & 0.628 & 0.00 & 0.829/0.362 & 0.700 & 0.615/0.257 & 0.491 \\ MSTLLF & \(3.42\pm 1.030\) & \(4.00\pm 0.805\) & \(3.49\pm 0.790\) & \(3.79\pm 0.770\) & 0.774 & **0.48** & 0.790/0.366 & 0.534 & 0.50 & 0.651/0.323 & 0.882 \\ HRQL & \(27.68\pm 13.449\) & \(17.95\pm 11.045\) & \(27.00\pm 13.578\) & \(18.31\pm 13.688\) & **0.000** * & **0.74** & 7.004/12.469 & **0.000** * & **0.76** & 6.793/10.591 & 0.899 \\ \hline \hline \end{tabular} VAS = Visual Analog Scale; ODI = Observedity modality; FTF = finger-to-floor distance; TRLF = trunk right lateral flexion; TLLF = trunk left lateral flexion; HF = hip flexion; MSTF = muscle strength trunk forward flexion; MSTF = muscle strength trunk extension; MSTRF = muscle strength trunk left lateral flexion; HRQL = health-related quality of life; * \(p<0.05\). The data written in bold characters emphasize a statistically significant difference.  
\end{table} 
Table 3: The outcome changes in both groups after two weeks of intervention (confidence interval 95%, mean \(\pm\) SD). the physical therapist specialized in lumbar disk disease recovery must choose the most suitable methods for the patient's rehabilitation. The current study has some significant limitations. First, the intervention time was limited to two weeks. One possible explanation for the comparable results in both groups is that the study time was too short. As a result, new research with a longer study period is required to investigate the changing impacts at different time points. The second limitation is that we conducted a single-center study and had a small sample size. Therefore, more research with a bigger sample size and a comparison of treatment based on gender is required to confirm the benefits of Vojta therapy over a longer length of time. In conclusion, we discovered substantial impacts of improving symptoms, following either Vojta therapy paired with physical therapy, or physical therapy alone, in our study.